Abstract:Abstract Background: Immune checkpoint inhibitors (ICI) have improved patient overall and progression-free survival in some cancer types but yielded limited success in breast cancer. Phase-III clinical trials in triple negative breast cancer (TNBC) patients, who harbor extensive tumor-infiltrating lymphocytes within tumor stroma, have demonstrated increased progression-free survival (IMpassion130) and pathologic complete response (KEYNOTE-522). Consequently, combinations of ICI and chemotherapy have been FDA-approved for metastatic TNBC patients, and potentially in the early breast cancer setting. Despite FDA-approval, the therapeutic benefit of ICI alone and the most efficacious chemotherapy combinations are poorly characterized. Objective: We sought to model ICI response in vivo to elucidate the mechanisms responsible for immunotherapy efficacy in breast cancer and ascertain the therapeutic benefits of different chemotherapeutic combinations with ICI. Methods: In this study, we used an immunocompetent EMT6 orthotopic mammary tumor model to investigate the efficacy of single-agent immunotherapy and in combination with standard-of-care chemotherapy (paclitaxel [PAC] or doxorubicin [DOX]). We used single-cell RNA sequencing to analyze the cellular landscape of the primary tumor in response to combinatorial therapeutic strategies. Additionally, we serially sampled and analyzed peripheral blood from mice with differential responses by bulk and T-cell receptor (TCR) sequencing to identify systemic genetic alterations and T-cell expansion. Results: Single-agent anti-PD-L1 robustly suppressed primary tumor growth (p =0.0046) and extended survival (p<0.0001) beyond the isotype control group. While either PAC or DOX demonstrated moderate therapeutic efficacy, neither agent potentiated single-agent anti-PD-L1 benefit. Interestingly, despite using a genetically identical tumor model and murine host, anti-PD-L1 induced heterogeneous responses, ranging from complete response to complete intrinsic resistance. The longitudinal analysis of peripheral blood from heterogeneously responding mice uncovered signatures of myeloid cell recruitment corresponding to transient responses ultimately converting to resistance. We also identified specific clonal T cell expansion present only in responders. Single-cell transcriptomic profiling of the tumor microenvironment revealed an increase of T cells and natural killer cells and reduction of regulatory T cells in the combination groups versus chemotherapy alone, although this did not translate into improved benefit. Finally, we performed gene-set enrichment analysis on infiltrating T cells and identified a robust signature of cytotoxic T cell activation characterized by a significant enrichment in inflammatory pathways in both single-agent anti-PD-L1 and in combination with chemotherapy. Conclusions: This study identifies a heterogeneously ICI-responsive in vivo model that emulates TNBC patient response to combinatorial ICI approaches. We describe the efficacy of single-agent ICI in upregulating cytotoxic immune cell infiltration and expansion within the primary tumor, thereby diminishing tumor growth and enhancing survival. Moreover, this study describes differential responses in a genetically similar host, which reflects heterogeneous patient response to ICI. Further characterization may identify systemic biomarkers and tumor antigen-specific T cell clones to accurately predict immunotherapy response in patients and uncover mechanisms for sensitizing tumors refractory to ICI. This study also has potentially significant clinical implications for re-evaluating the benefits of chemotherapy in combination with ICI in TNBC patients. Citation Format: Ann Hanna, Xiaopeng Sun, Paula I. Gonzalez-Ericsson, Violeta M. Sanchez, Melinda E. Sanders, Justin M. Balko. Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1 [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-04-03.

Abstract 1221: Mitomycin C Induces Programed Cell Death Ligand 1 Overexpression but Enhances Anticancer Immunity in None Small Cell Lung Cancer

Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer

Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer

Abstract P4-06-21: MEK Inhibitor Cobimetinib Induces Immunogenic Cell Death and Immune-Modulatory Effects in Triple Negative Breast Cancer

Effect of Cisplatin Alone or Combined with Monoclonal Anti-Programmed Death Ligand-1 Anti-Body on Lung Adenocarcinoma Cell Line SPCA-1 and T Lymphocytes

Abstract 5191: BCL-2 inhibitor APG-2575 promotes anti-tumor immunity through converting tumor-associated macrophages into M1 phenotype in non-small cell lung cancer

Inhibition of MYC Suppresses Programmed Cell Death Ligand-1 Expression and Enhances Immunotherapy in Triple-Negative Breast Cancer

Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Abstract 2726: Host myeloid response drives anti-PD-L1 resistance in murine models of triple negative breast cancer

Abstract A77: Antibody Targeting Tumor-Derived Soluble NKG2D Ligand Smic Provides Dual Costimulation of CD8 T Cells and Enables Smic+ Tumors to Respond to PD1/PD-L1 Blockade Therapy

Mitomycin C modulates tumor microenvironment and enhances radiosensitivity in rectal cancer

Abstract P1-04-03: Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1

Abstract 5515: Combination of recombinant murine IL-12 and anti-PD-1 induced synergistic anti-tumor response

Abstract 3480: Modulating DNA and Histone Methylation As a Therapeutic Target for Non-Small Cell Lung Cancer by Shifting the Composition of Immune Cells

Abstract 2664: Targeting PD-L1/CMTM6 in myeloid cells results in elevated release of CCL2 to improve CD8 T cell-mediated antitumor response

Abstract 4977: Immunogenic Chemotherapy Synergize PD-1 Blockade by Enhancing Dendritic Cells Infiltration in Triple-Negative Breast Cancer (TNBC)

Abstract 1375: Abundance of KLRB1+ (CD161) T cells in anti-PD1 non responders coupled with enhanced tumor cytotoxicity of anti-CD161 (IMT-009) with anti-PD1 makes it a rational target for combination with anti-PD-(L)1 immunotherapy

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

Bcl-2 Inhibitor Apg-2575 Promotes Anti-Tumor Efficacy Of Immune Checkpoint Blockade Through Converting Tumor-Associated Macrophages Into M1 Phenotype In Non-Small Cell Lung Cancer.

Cisplatin Nanoparticles Promote Intratumoral CD8 + T Cell Priming via Antigen Presentation and T Cell Receptor Crosstalk

Abstract 4026: The combination of DLL4/VEGF-a blockade and immunomodulation can eliminate MHC class I negative tumors in mice